MarketWatch.com - Top Stories

Moderna is counting on its product pipeline to resuscitate its ailing stock

The company hopes to deliver “up to 10 product approvals through 2027.”

Feb 14, 2025 - 14:31
 0
Moderna is counting on its product pipeline to resuscitate its ailing stock
The company hopes to deliver “up to 10 product approvals through 2027.”
Read More

Tags:

Previous Article

India's wholesale inflation holds steady in January at 2.31%

Next Article

Americans Are Spoiling Their Pets. Buy This Gourmet Meal Maker’s Stock.

Related Posts

Why the options market is hotter than ever and could be on track for more records

Why the options market is hotter than ever and could be...

Feb 12, 2025  0

One of the Japanese trading houses that Buffett owns ag...

Feb 19, 2025  0

What happens to the floral townhome of singer Lily Allen and ‘Stranger Things’ actor David Harbour if they split?

What happens to the floral townhome of singer Lily Alle...

Feb 10, 2025  0